The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute
Pascal V. Grundler,
Robert Eichler,
Zeynep Talip,
P. August Schubiger,
Roger Schibli,
Nicholas P. van der Meulen
Affiliations
Pascal V. Grundler
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland
Robert Eichler
Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland
Zeynep Talip
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerlan
P. August Schubiger
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland
Roger Schibli
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, CH-8093 Zurich, Switzerland
Nicholas P. van der Meulen
Center of Radiopharmaceutical Sciences PSI-USZ-ETH, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland; Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungstrasse 111, CH-5232 Villigen-PSI, Switzerland
Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Research. The facilities used for this purpose have evolved substantially over the last five decades. Many radiometals in use today, as radiopharmaceuticals, are for the diagnosis and treatment of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, developments at these facilities are lacking. Currently, the fixed 72 MeV proton beam at PSI is degraded at IP2 irradiation station to provide the desired energy to irradiate targets to produce the likes of 44Sc, 43Sc and 64Cu as a proof of principle, which are of great interest to the nuclear medicine community. This development work can then be implemented at facilities containing medical cyclotrons. A history of the development of radionuclides at PSI, along with current development and projects with partner institutions, is described.
